|
1
|
Zörnig M, Hueber A, Baum W and Evan G:
Apoptosis regulators and their role in tumorigenesis. Biochim
Biophys Acta. 1551:F1–F37. 2001.
|
|
2
|
Thompson CB: Apoptosis in the pathogenesis
and treatment of disease. Science. 267:1456–1462. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Evan GI and Vousden KH: Proliferation,
cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lorenz HM, Herrmann M, Winkler T, Gaipl U
and Kalden JR: Role of apoptosis in autoimmunity. Apoptosis.
5:443–449. 2000. View Article : Google Scholar
|
|
5
|
Itoh N, Yonehara S, Ishii A, et al: The
polypeptide encoded by the cDNA for human cell surface antigen Fas
can mediate apoptosis. Cell. 66:233–243. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Oehm A, Behrmann I, Falk W, et al:
Purification and molecular cloning of the APO-1 cell surface
antigen, a member of the tumor necrosis factor/nerve growth factor
receptor superfamily. Sequence identity with the Fas antigen. J
Biol Chem. 267:10709–10715. 1992.
|
|
7
|
Nagata S: Apoptosis by death factor. Cell.
88:355–365. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Butler LM, Hewett PJ, Butler WJ and Cowled
PA: Down-regulation of Fas gene expression in colon cancer is not a
result of allelic loss or gene rearrangement. Br J Cancer.
77:1454–1459. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lee SH, Shin MS, Park WS, et al:
Alterations of Fas (APO-1/CD95) gene in transitional cell
carcinomas of urinary bladder. Cancer Res. 59:3068–3072.
1999.PubMed/NCBI
|
|
10
|
Shimonishi T, Isse K, Shibata F, et al:
Up-regulation of Fas ligand at early stages and down-regulation of
Fas at progressed stages of intrahepatic cholangiocarcinoma reflect
evasion from immune surveillance. Hepatology. 32:761–769. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nunobiki O, Ueda M, Toji E, et al: Genetic
polymorphism of cancer susceptibility genes and HPV infection in
cervical carcinogenesis. Patholog Res Int.
2011:3640692011.PubMed/NCBI
|
|
12
|
Huang QR, Morris D and Manolios N:
Identification and characterization of polymorphisms in the
promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol.
34:577–582. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sun T, Zhou Y, Li H, et al: FASL -844C
polymorphism is associated with increased activation-induced T cell
death and risk of cervical cancer. J Exp Med. 202:967–974. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kordi Tamandani DM, Sobti RC and Shekari
M: Association of Fas-670 gene polymorphism with risk of cervical
cancer in North Indian population. Clin Exp Obstet Gynecol.
35:183–186. 2008.
|
|
15
|
Scarinci IC, Garcia FA, Kobetz E, et al:
Cervical cancer prevention: new tools and old barriers. Cancer.
116:2531–2542. 2010.PubMed/NCBI
|
|
16
|
Anorlu RI: Cervical cancer: the
sub-Saharan African perspective. Reprod Health Matters. 16:41–49.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Moore MA, Manan AA, Chow KY, et al: Cancer
epidemiology and control in peninsular and island South-East Asia -
past, present and future. Asian Pac J Cancer Prev. 2:81–98.
2010.PubMed/NCBI
|
|
18
|
Langmár Z, Németh M and Kornya L: Cervical
cancer screening in Hungary - epidemiologic, historical and
methodologic aspects. Orv Hetil. 152:2063–2066. 2010.(In
Hungarian).
|
|
19
|
Parkin DM, Sitas F, Chirenje M, Stein L,
Abratt R and Wabinga H: Part I: Cancer in indigenous Africans -
burden, distribution, and trends. Lancet Oncol. 9:683–692. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Guan P, Howell-Jones R, Li N, Bruni L, de
Sanjosé S, Franceschi S and Clifford GM: Human papillomavirus types
in 115,789 HPV-positive women: a meta-analysis from cervical
infection to cancer. Int J Cancer. 131:2349–2359. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pate Capps N, Stewart A and Burns C: The
interplay between secondhand cigarette smoke, genetics, and
cervical cancer: a review of the literature. Biol Res Nurs.
10:392–399. 2009.PubMed/NCBI
|
|
22
|
Dikshit R, Gupta PC, Ramasundarahettige C,
et al: Cancer mortality in India: a nationally representative
survey. Lancet. 12:1807–1816. 2012. View Article : Google Scholar
|
|
23
|
Zucchi F, da Silva ID, Ribalta JC, et al:
Fas/CD95 promoter polymorphism gene and its relationship with
cervical carcinoma. Eur J Gynaecol Oncol. 30:142–144.
2009.PubMed/NCBI
|
|
24
|
Kang S, Dong SM, Seo SS, Kim JW and Park
SY: FAS -1377 G/A polymorphism and the risk of lymph node
metastasis in cervical cancer. Cancer Genet Cytogenet J. 180:1–5.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ueda M, Terai Y, Kanda K, et al: Fas gene
promoter -670 polymorphism in gynecological cancer. Int J Gynecol
Cancer. 16(Suppl 1): 179–182. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zoodsma M, Nolte IM, Schipper M, et al:
Interleukin-10 and Fas polymorphisms and susceptibility for
(pre)neoplastic cervical disease. Int J Gynecol Cancer. 3:282–290.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lai HC, Lin WY, Lin YW, Chang CC, Yu MH,
Chen CC and Chu TY: Genetic polymorphisms of FAS and FASL
(CD95/CD95L) genes in cervical carcinogenesis: an analysis of
haplotype and gene-gene interaction. Gynecol Oncol. 99:113–118.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ueda M, Hung YC, Terai Y, et al: Fas gene
promoter -670 polymorphism (A/G) is associated with cervical
carcinogenesis. Gynecol Oncol. 98:129–133. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dybikowska A, Sliwinski W, Emerich J and
Podhajska AJ: Evaluation of Fas gene promoter polymorphism in
cervical cancer patients. Int J Mol Med. 14:475–478.
2004.PubMed/NCBI
|
|
30
|
Lai HC, Sytwu HK, Sun CA, et al: Single
nucleotide polymorphism at Fas promoter is associated with cervical
carcinogenesis. Int J Cancer. 103:221–225. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chatterjee K, Engelmark M, Gyllensten U,
et al: Fas and FasL gene polymorphisms are not associated with
cervical cancer but differ among black and mixed-ancestry South
Africans. BMC Res Notes. 26:2382009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang Z, Xue H, Gong W, Wang M, Yuan L,
Han S and Zhang Z: FAS promoter polymorphisms and cancer risk: a
meta-analysis based on 34 case-control studies. Carcinogenesis.
30:487–493. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Weir BS: Genetic data analysis II: Methods
for discrete population genetic data. Sunderland Mass: Sinauer
Associates; 1996
|
|
34
|
Higgins JP, Thompson SG, Deeks JJ and
Altman DG: Measuring inconsistency in meta-analyses. BMJ.
327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zintzaras E, Chatzoulis DZ, Karabatsas CH
and Stefanidis I: The relationship between C677T
methylenetetrahydrofolate reductase gene polymorphism and
retinopathy in type 2 diabetes: a meta-analysis. J Hum Genet.
50:267–275. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Begg CB and Mazumdar M: Operating
characteristics of a rank correlation test for publication bias.
Biometrics. 50:1088–1101. 1994. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Engelmark MT, Renkema KY and Gyllensten
UB: No evidence of the involvement of the Fas -670 promoter
polymorphism in cervical cancer in situ. Int J Cancer.
112:1084–1085. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lerma E, Romero M, Gallardo A, et al:
Prognostic significance of the Fas-receptor/Fas-ligand system in
cervical squamous cell carcinoma. Virchows Arch. 452:65–74. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li H, Guo HY, Sun T, Zhou YF, Lin DX,
Zhang WH and Qiao J: Association between Fas/Fas L genes promoter
polymorphisms and pathogenic risk of cervical cancer. Chin J Oncol.
31:38–41. 2009.(In Chinese).
|
